# Yi Ba

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yi-ba/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,514 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 60 |
| i10-index | 156 |
| Last Known Institution | South China Normal University |
| OpenAlex ID | https://openalex.org/A5037658093 |
| ORCID iD | https://orcid.org/0000-0003-0255-4376 |
| Works | 390 |

## Researcher papers

- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial](https://scholariq.org/papers/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [MicroRNA in disease regulation](https://scholariq.org/topics/microrna-in-disease-regulation/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Researcher university

- [South China Normal University](https://scholariq.org/institutions/south-china-normal-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.